General Request for Proposals – The Alzheimer’s Drug Discovery Foundation (ADDF)



Topic: Alzheimer.

Destination: The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer’s and related dementias. This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information). We have dedicated our funding to several key areas:

  • Translational research to develop new drugs and build preclinical evidence
  • IND-enabling studies and early-stage clinical trials for novel and repurposed drugs
  • Development and validation of plasma, CSF, neuroimaging and digital biomarkers
  • Epidemiological studies and comparative effectiveness research

Applications are reviewed throughout the year through our core programs. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.


  • Drug development: up to 600,000 $.
  • Program to accelerate clinical trials: up to 3 million $.
  • Neuroimaging and CSF biomarker development program: up to 600,000 $.
  • Prevention pipeline: up to 3 million $ for clinical trials.

Duration: 1 year.

Are you interested in this call?

Are you interested?

Fill out the form below to receive more information: